Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical outcomes for PriMatrix® Dermal Repair Scaffold for the management of hard to heal diabetic foot ulcers (DFUs). This study is one of the largest DFU randomized controlled trials (RCTs) ever completed with more than 100 patients per treatment group and demonstrated that in most cases, one application of PriMatrix plus standard of care (SOC) healed 60% of DFUs in 12 weeks versus 35% of DFUs that healed in 12 weeks with SOC for the per protocol analysis.
This data was recently published by lead investigator, John Lantis, M.D., FACS, from Mount Sinai Health System in New York, in the Journal of Wound Care, the definitive wound-care journal and leading source of up-to-date research and clinical information on everything related to tissue viability … read more